Isabel Aznarez
Fundador en STOKE THERAPEUTICS, INC. .
Perfil
Isabel Aznarez is the founder of Stoke Therapeutics, Inc. which was founded in 2014.
She holds the title of Senior Vice President-Discovery Research at Stoke Therapeutics, Inc. Dr. Aznarez's current job is as a Director at Oligonucleotide Therapeutics Society, Inc. since 2019.
Dr. Aznarez obtained a doctorate degree from the University of Toronto in 2006 and also has an undergraduate degree from Universidad De La Republica Uruguay.
Cargos activos de Isabel Aznarez
| Empresas | Cargo | Inicio |
|---|---|---|
| STOKE THERAPEUTICS, INC. | Fundador | 01/06/2014 |
Oligonucleotide Therapeutics Society, Inc.
 Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Director/Miembro de la Junta | 01/01/2019 |
Formación de Isabel Aznarez.
| University of Toronto | Doctorate Degree |
| Universidad De La Republica Uruguay | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| STOKE THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Commercial Services |
- Bolsa de valores
- Insiders
- Isabel Aznarez
